FFR-guided PCI plus TAVI was non-inferior and statistically superior to SAVR plus CABG for the composite endpoint at 1 year in elderly patients with severe aortic stenosis and complex coronary artery disease.
Percutaneous treatment achieved lower all-cause mortality (0% vs 10%) and reduced life-threatening bleeding compared to surgical treatment.
The TCW trial is the first head-to-head randomized trial comparing these two strategies in this high-risk population.
